产品名称：Human MUC1 Antibody (Clivatuzumab, Research Use)
产品编号：NBR-0250
针对靶点：MUC1
抗体药商品名：Clivatuzumab
抗体药描述：Yttrium (90 Y) Clivatuzumab Tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate (ADC) designed by Immunomedics, Inc. for the treatment of pancreatic cancer. The antibody part, clivatuzumab (also known as PAM4), which targets mucin 1 (MUC1), is conjugated with the chelating agent 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA), tetraxetan, and radiolabeled with the beta-emitting radioisotope Yttrium-90, a radioisotope which destroys the tumor cells. 产品外观：Transparent Liquid
分子量：~150kDa
CAS：N/A
溶解度：Water; PBS, TBS Buffer等
表达系统：CHO Expressed
抗体亚型：Ab. Isotype - IgG

  Gene Name: MUC1
Synonyms: ADMCKD; ADMCKD1; CD227; MCD; MCKD; MCKD1; PEM; PUM
Target Description: The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.
Ensembl: ENSG00000185499 
Uniprot: P15941